BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

CanSinoBIO Showcases Vaccine Innovation and Global Health Commitment at 2025 World Government Summit

CanSino Biologics Inc. (CanSinoBIO or the Company), a leading Chinese vaccine innovator, has been invited to the 2025 World Government Summit in Dubai...

February 18, 2025 | News

TAHO Pharmaceuticals’ Apixaban Oral Dissolving Film Shows Positive Results in Pivotal Study

TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The s...

February 18, 2025 | News

RemeGen Presents Promising Phase II Trial Results for Disitamab Vedotin and Toripalimab in Muscle-Invasive Bladder Cancer at ASCO GU 2025

RemeGen Co., Ltd. (RemeGen) has announced new efficacy and safety data from the Phase II clinical trial (NCT05297552, Study ID: RC48-C017) evaluating Disit...

February 17, 2025 | News

Taiwan's Caliway Biopharmaceuticals Reports Groundbreaking Results for CBL-514 in U.S. and Canada Phase 2b Study

Caliway Biopharmaceuticals unveiled the impressive results of its second Phase 2b clinical study (CBL-0205) for CBL-514, the world’s first in...

February 11, 2025 | News

Allurion Technologies to Initiate Clinical Study Combining Allurion Program with GLP-1 Therapy to Transform Obesity Care

Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced its ...

January 24, 2025 | News

Hyundai ADM Bio Showcases Innovative Oral Chemotherapy OTX-M at Biotech Showcase 2025

Hyundai ADM Bio (Co-CEOs Taek-Sung Kim and Kwang-Hee Kim) announced the results of its preclinical study on the oral anti-cancer drug O...

January 23, 2025 | News

Ascletis Pharma Reports Promising Results for ASC30 Oral Tablet in Obesity Treatment

ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose ...

January 22, 2025 | News

Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 in Advanced Pancreatic Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

January 16, 2025 | News

China Approves Sarclisa-Pd for Relapsed Multiple Myeloma, Backed by Pivotal Trial and Real-World Data.

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa ...

January 13, 2025 | News

Global Frenzy for TCE Bispecific Antibodies: Billion-Dollar Deals Propel Chinese Biotech to the Forefront

The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantical...

January 10, 2025 | News

2025 Pharma and Medical Device Trends for Manufacturing Leaders

2025 Pharma and Medical Device Trends for Manufacturing LeadersKey Insights for Regulated Manufacturing Today and Tomorrow In ...

January 07, 2025 | News

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy After Pfizer Ends Collaboration

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctoco...

January 02, 2025 | News

25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare

The pharmaceutical industry is bracing for a transformative year as 2025 approaches, with 25 high-revenue drugs set to lose patent protection. These expira...

December 27, 2024 | Analysis

Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025

Antibody-Drug Conjugates (ADCs) represent a paradigm shift in oncology, offering targeted cancer treatment that minimizes collateral damage to healthy cell...

December 23, 2024 | News

Stay Connected